Ganirelix Acetate API (CAS No. 129311-55-3) is a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist associated with fertility treatment, reproductive medicine, and controlled ovarian stimulation pharmaceutical applications.
Ganirelix Acetate acts by competitively blocking GnRH receptors on pituitary gonadotroph cells. This receptor antagonism produces rapid and reversible suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion.
Unlike GnRH agonists, Ganirelix Acetate directly antagonizes the GnRH receptor without producing an initial gonadotropin flare response. Its rapid suppression of pituitary gonadotropin secretion is particularly relevant to assisted reproductive technology and controlled ovarian hyperstimulation pharmaceutical protocols.
Ganirelix Acetate is associated with pharmaceutical products developed to inhibit premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation.
Pharmaceutical and peptide companies sourcing Ganirelix Acetate API commonly evaluate peptide identity, HPLC purity, peptide content, molecular mass, amino acid sequence, related peptides, acetate content, water content, residual solvents, residual synthesis reagents, and batch-to-batch consistency.
Because Ganirelix Acetate is a complex synthetic decapeptide containing multiple defined stereochemical centers, control of deletion sequences, truncated peptides, epimer-related impurities, oxidation products, and peptide synthesis-related impurities is important during API qualification.
Swapnroop Drugs and Pharmaceuticals supplies Ganirelix Acetate API for qualified pharmaceutical research, fertility drug development, peptide formulation, analytical, injectable product development, and regulated manufacturing requirements with product-specific quality documentation, peptide-appropriate packaging, and reliable supply-chain coordination.
Pharmaceutical and peptide manufacturers evaluating Ganirelix Acetate API commonly focus on:
Peptide impurity profiling is particularly important for Ganirelix Acetate because peptide synthesis may generate closely related sequence impurities that require appropriate chromatographic separation, characterization, and control.
Acetate counter-ion content is another important quality consideration because the salt composition and peptide content should be evaluated according to the approved Ganirelix Acetate API specification.
Ganirelix Acetate API is primarily associated with:
Ganirelix Acetate pharmaceutical products are associated with inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation.
Ganirelix Acetate is a GnRH receptor antagonist associated with assisted reproductive technology and controlled ovarian stimulation.
Pharmaceutical companies evaluating Ganirelix Acetate API may review:
Product-specific specifications should be evaluated according to the intended injectable dosage form, formulation process, target regulatory market, and approved pharmaceutical development requirements.
Ganirelix and Ganirelix Acetate should be treated as separate product identities for procurement, quality, specification, and website purposes.
Ganirelix free peptide is identified by CAS No. 124904-93-4.
Ganirelix Acetate is identified by CAS No. 129311-55-3 and is the acetate salt form associated with marketed subcutaneous injection products.
Procurement, formulation, quality, and regulatory teams should confirm the exact peptide form and applicable specification before commercial sourcing.
Swapnroop Drugs and Pharmaceuticals supports qualified pharmaceutical and peptide-development customers with:
Ganirelix Acetate API is supplied in secure peptide-appropriate pharmaceutical packaging selected according to product quantity, stability requirements, moisture protection requirements, and customer specifications.
Product-appropriate primary containers and protective secondary packaging may be used according to the supplied material specification.
Available packaging configurations may include:
Packaging configuration, MOQ, commercial quantity, storage requirements, and shipment conditions are confirmed according to the approved product specification and customer enquiry.
Store Ganirelix Acetate API under the controlled storage conditions specified in the approved product documentation.
Protect the peptide material from excessive moisture, heat, direct light, contamination, and unsuitable environmental exposure.
Temperature excursions should be avoided where restricted by the product-specific stability specification.
Handling should be performed by trained personnel using approved peptide and pharmaceutical raw material handling procedures and applicable safety documentation.
Product-specific storage and handling requirements should be confirmed from the approved COA, SDS, specification, and stability documentation.
Swapnroop Drugs and Pharmaceuticals provides Ganirelix Acetate API bulk supply and export support in India for qualified pharmaceutical manufacturers, fertility drug developers, peptide companies, injectable formulation developers, analytical laboratories, and pharmaceutical procurement customers.
For Ganirelix Acetate API price, CAS No. 129311-55-3, peptide purity, HPLC specification, acetate content, related peptide profile, COA availability, MOQ, packaging, and export enquiries, contact our pharmaceutical sales team.
Get Bulk Quote via WhatsApp